Akebia Therapeutics, Inc.
DE ˙ DB ˙ US00972D1054
0,83 € ↓ -0,02 (-2,69%)
2026-06-03
AKTIENPREIS
SecurityDE:AX9 / Akebia Therapeutics, Inc.
InstitutionBarclays Plc
Latest Disclosed Ownership923,507 shares
Latest Disclosed Value $ 1,486,847
Barclays Plc ownership in AX9 / Akebia Therapeutics, Inc.

On February 13, 2026 - Barclays Plc filed a 13F-HR form disclosing ownership of 923,507 shares of Akebia Therapeutics, Inc. (DE:AX9) valued at $1,231,958 USD as of December 31, 2025. The entity filed a previous 13F-HR/A on March 31, 2026 disclosing 1,180,233 shares of Akebia Therapeutics, Inc.. This represents a change in shares of -21.75% during the quarter. The current value of the position is $767,250 USD.

Barclays Plc has a history of taking positions in derivatives of the underlying security (AX9) in the form of stock options. The firm currently holds call options representing 0 of underlying shares valued at $0 USD and put options representing 0 of underlying shares valued at $0 USD .

Note: prior versions of this page mistakenly stated that the share values represented the number of options, not the number of underlying shares. For more information on the data backing these reports, please see the SEC document Frequently Asked Questions About Form 13F.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Institutional Put/Call Ratios
(Premium Subscription Required)

In addition to reporting standard equity and debt issues, institutions with more than 100MM assets under management must also disclose their put and call option holdings. Since put options generally indicate negative sentiment, and call options indicate positive sentiment, we can get a sense of the overall institutional sentiment by plotting the ratio of puts to calls. The chart to the right plots the historical put/call ratio for this instrument.

Using Put/Call Ratio as an indicator of investor sentiment overcomes one of the key deficiencies of using total institutional ownership, which is that a significant amount of assets under management are invested passively to track indices. Passively-managed funds do not typically buy options, so the put/call ratio indicator more closely tracks the sentiment of actively-managed funds.

DE:AX9 / Akebia Therapeutics, Inc. Historical Put/Call Ratio
Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-02-13 2025-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 923,507 -256,726 -21.75 1,487 -53.88 0.0004
2026-03-31 2025-09-30 13F/A-3 AKEBIA THERAPEUTICS COM 00972D105 1,180,233 195,721 19.88 3,222 -10.08 0.0007
2026-03-19 2025-09-30 13F/A-2 AKEBIA THERAPEUTICS COM 00972D105 273,085 -711,427 360 0.0001
2025-11-12 2025-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 1,180,233 195,721 3,222 0.0007
2026-02-27 2025-06-30 13F/A-2 AKEBIA THERAPEUTICS COM 00972D105 984,512 676,377 219.51 3,584 506.26 0.0008
2025-08-14 2025-06-30 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 984,512 676,377 4 0.0008
2025-08-13 2025-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 984,512 676,377 4 0.0003
2026-03-17 2025-03-31 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 308,135 -67,360 -17.94 592 -17.11 0.0002
2025-05-15 2025-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 308,135 -67,360 1 0.0002
2026-03-19 2024-12-31 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 375,495 102,410 37.50 713 98.06 0.0002
2025-02-13 2024-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 375,495 102,410 1 0.0002
2026-03-31 2024-09-30 13F/A-2 AKEBIA THERAPEUTICS COM 00972D105 273,085 200,482 276.13 360 386.49 0.0001
2024-11-19 2024-09-30 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 273,085 200,482 0 0.0001
2024-11-15 2024-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 273,085 200,482 0 0.0000
2026-03-23 2024-06-30 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 72,603 -137,397 -65.43 74 -80.73 0.0000
2024-08-14 2024-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 72,603 -137,397 0 0.0000
2026-03-24 2024-03-31 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 210,000 210,000 384 0.0001
2024-05-15 2024-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 210,000 210,000 0 0.0001
2022-08-12 2022-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 0 -84,146 -100.00 0 -100.00
2022-05-16 2022-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 84,146 -200,624 -70.45 61 -90.51 0.0000
2022-02-23 2021-12-31 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 284,770 96,413 51.19 643 18.63 0.0002
2022-02-14 2021-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 284,770 96,413 643 0.0001
2021-11-09 2021-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 188,357 19,081 11.27 542 -15.58 0.0002
2021-08-13 2021-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 169,276 -67,942 -28.64 642 -20.15 0.0003
2021-05-13 2021-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 237,218 73,426 44.83 804 75.55 0.0004
2021-02-11 2020-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 163,792 -20,701 -11.22 458 -1.08 0.0002
2020-11-12 2020-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 184,493 49,439 36.61 463 -74.75 0.0003
2020-08-12 2020-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 135,054 1,297 0.97 1,834 80.87 0.0014
2020-05-13 2020-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 133,757 -37,133 -21.73 1,014 -6.11 0.0008
2020-02-10 2019-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 170,890 51,902 43.62 1,080 131.26 0.0006
2019-11-15 2019-09-30 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 118,988 -10,615 -8.19 467 -25.64 0.0003
2019-11-14 2019-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 118,988 -10,615 467 107.9709
2019-08-14 2019-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 129,603 20,912 19.24 628 -29.52 0.0004
2019-05-15 2019-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 108,691 106,653 5,233.22 891 8,000.00 0.0006
2019-02-14 2018-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 2,038 -93,007 -97.86 11 -98.69 0.0000
2018-11-14 2018-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 95,045 80,240 541.98 839 466.89 0.0006
2018-08-14 2018-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 14,805 -16,340 -52.46 148 -50.00 0.0001
2018-05-15 2018-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 31,145 13,161 73.18 296 10.45 0.0002
2018-02-14 2017-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 17,984 16,416 1,046.94 268 793.33 0.0002
2017-11-14 2017-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 1,568 -12,330 -88.72 30 -84.92 0.0000
2017-08-14 2017-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 13,898 13,020 1,482.92 199 2,111.11 0.0002
2017-05-15 2017-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 878 -3,174 -78.33 9 -79.07 0.0000
2017-02-14 2016-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 4,052 3,704 1,064.37 43 1,333.33 0.0000
2016-11-14 2016-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 348 -145 -29.41 3 -25.00 0.0000
2016-08-12 2016-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 493 300 155.44 4 100.00 0.0000
2016-05-16 2016-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 193 -266 -57.95 2 -66.67 0.0000
2016-02-12 2015-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 459 -7,918 -94.52 6 -92.00 0.0000
2015-11-13 2015-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 8,377 7,854 1,501.72 75 1,150.00 0.0001
2015-08-14 2015-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 523 49 10.34 6 20.00 0.0000
2015-05-19 2015-03-31 13F/A-1 AKEBIA THERAPEUTICS COM 00972D105 474 29 6.52 5 25.00 0.0000
2015-05-14 2015-03-31 13F AKEBIA THERAPEUTICS COM 00972D105 474 5
2015-02-13 2014-12-31 13F AKEBIA THERAPEUTICS COM 00972D105 445 364 449.38 4 100.00 0.0000
2014-11-14 2014-09-30 13F AKEBIA THERAPEUTICS COM 00972D105 81 -2,400 -96.74 2 -97.01 0.0000
2014-08-14 2014-06-30 13F AKEBIA THERAPEUTICS COM 00972D105 2,481 2,481 67 0.0001
Disclosed Call Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share
Price
Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2020-11-12 2020-09-30 13F AKEBIA THERAPEUTICS OPT Call 0 -100.00 0 -100.00 n/a n/a n/a
2020-08-12 2020-06-30 13F AKEBIA THERAPEUTICS OPT Call 1,200 0.00 16 77.78 n/a n/a n/a
2020-05-13 2020-03-31 13F AKEBIA THERAPEUTICS OPT Call 1,200 -24.58 9 -10.00 n/a n/a n/a
2020-02-10 2019-12-31 13F AKEBIA THERAPEUTICS OPT Call 1,591 -73.44 10 -56.52 n/a n/a n/a
2019-11-15 2019-09-30 13F/A AKEBIA THERAPEUTICS OPT Call 5,991 7.15 23 -14.81 n/a n/a n/a
2019-11-14 2019-09-30 13F AKEBIA THERAPEUTICS OPT Call 5,991 23 n/a n/a n/a
2019-08-14 2019-06-30 13F AKEBIA THERAPEUTICS OPT Call 5,591 80.88 27 8.00 n/a n/a n/a
2019-05-15 2019-03-31 13F AKEBIA THERAPEUTICS OPT Call 3,091 -8.41 25 31.58 n/a n/a n/a
2019-02-14 2018-12-31 13F AKEBIA THERAPEUTICS OPT Call 3,375 19 n/a n/a n/a
Disclosed Put Options
File
Date
Effective
Date
Form Security Class ID Opt Avg Share Price Shares ΔShares
(%)
Value
(x1000)
ΔValue
(%)
Prior Allocation
(%)
Allocation
(%)
ΔAllocation
(%)
Cost Basis
(x1000)
Profit
(x1000)
Return
(%)
2020-08-12 2020-06-30 13F AKEBIA THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2020-05-13 2020-03-31 13F AKEBIA THERAPEUTICS OPT Put 10,400 5,100.00 79 7,800.00 n/a n/a n/a
2020-02-10 2019-12-31 13F AKEBIA THERAPEUTICS OPT Put 200 0.00 1 0.00 n/a n/a n/a
2019-11-15 2019-09-30 13F/A AKEBIA THERAPEUTICS OPT Put 200 1 n/a n/a n/a
2019-11-14 2019-09-30 13F AKEBIA THERAPEUTICS OPT Put 200 1 n/a n/a n/a
2019-05-15 2019-03-31 13F AKEBIA THERAPEUTICS OPT Put 0 -100.00 0 -100.00 n/a n/a n/a
2019-02-14 2018-12-31 13F AKEBIA THERAPEUTICS OPT Put 4,811 27 n/a n/a n/a
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.